{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T15:37:11Z","timestamp":1770824231723,"version":"3.50.1"},"reference-count":34,"publisher":"BMJ","issue":"11","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Clin Pathol"],"accepted":{"date-parts":[[2016,3,22]]},"published-print":{"date-parts":[[2016,11]]},"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Hypomethylating agents (HMAs) exhibit clinical efficacy in patients with myelodysplastic syndromes (MDS) and myelodysplastic\/myeloproliferative neoplasms (MDS\/MPN). This study was performed to assess residual disease status by flow cytometry immunophenotyping (FCI) methods in patients with MDS or MDS\/MPN treated with HMAs, and correlate the findings with clinical response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>CD34+ myeloid precursors were assessed in 85 patients with MDS and MDS\/MPN treated with HMAs using FCI methods. Morphological, cytogenetic and molecular assessments were performed to evaluate the responses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After a median six cycles (3\u201319) of HMAs, 40 (47%) patients showed haematological improvement, 26 (63%) showed bone marrow (BM) and 20 (39%) cytogenetic response. However, CD34+ myeloid progenitors showed persistent immunophenotypic aberrancies in 72 (85%) patients, indeterminate in four (5%) and negative in nine (10%). Compared with pretreatment BM in a given patient, FCI abnormalities were reduced in 15 (20%) patients, similar in 37 (48%), increased in 15 (20%) and showed antigenic shift in nine (12%). Patients who achieved immunophenotypic improvement had a superior progression-free survival (p=0.031). In the subgroup of patients who underwent haematopoietic stem cell transplant (HSCT), 16\/19 (84%) patients who had a pre-HSCT positive FCI study became normal.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings show the difficulty in eradicating neoplastic myeloid precursors by HMA therapy, thereby resulting in ultimate treatment failure in most patients. Achieving immunophenotypic improvement helps to identify patients who may benefit from continuous HMA treatment. HSCT provides a potential cure for these patients by replenishing BM with normal haematopoietic stem cells.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jclinpath-2016-203715","type":"journal-article","created":{"date-parts":[[2016,4,15]],"date-time":"2016-04-15T23:25:04Z","timestamp":1460762704000},"page":"1001-1008","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["Persistence of immunophenotypically aberrant CD34+ myeloid progenitors is frequent in bone marrow of patients with myelodysplastic syndromes and myelodysplastic\/myeloproliferative neoplasms treated with hypomethylating agents"],"prefix":"10.1136","volume":"69","author":[{"given":"Lanshan","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"},{"name":"Department of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maitrayee","family":"Goswami","sequence":"additional","affiliation":[{"name":"Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark J","family":"Routbort","sequence":"additional","affiliation":[{"name":"Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L Jeffrey","family":"Medeiros","sequence":"additional","affiliation":[{"name":"Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey L","family":"Jorgensen","sequence":"additional","affiliation":[{"name":"Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sa A","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2016,4,15]]},"reference":[{"key":"2025112109553862000_69.11.1001.1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24102"},{"key":"2025112109553862000_69.11.1001.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2013.06.004"},{"key":"2025112109553862000_69.11.1001.3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70003-8"},{"key":"2025112109553862000_69.11.1001.4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.04.117"},{"key":"2025112109553862000_69.11.1001.5","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21792"},{"key":"2025112109553862000_69.11.1001.6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.6823"},{"key":"2025112109553862000_69.11.1001.7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.30.9245"},{"key":"2025112109553862000_69.11.1001.8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-10-4149"},{"key":"2025112109553862000_69.11.1001.9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-607341"},{"key":"2025112109553862000_69.11.1001.10","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25774"},{"key":"2025112109553862000_69.11.1001.11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-06-289280"},{"key":"2025112109553862000_69.11.1001.12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-07-098764"},{"key":"2025112109553862000_69.11.1001.13","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21224"},{"key":"2025112109553862000_69.11.1001.14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-239749"},{"key":"2025112109553862000_69.11.1001.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2012.05.001"},{"key":"2025112109553862000_69.11.1001.16","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23988"},{"key":"2025112109553862000_69.11.1001.17","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12477"},{"key":"2025112109553862000_69.11.1001.18","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21215"},{"key":"2025112109553862000_69.11.1001.19","unstructured":"Brunning RD , Germing U , Le Beau MM , et al . Myelodysplastic syndromes\/neoplasms. In: Swerdlow SH , Harris NL , Jaffe ES , et al ., eds. WHO classification of tumours of haematopoietic and lymphoid tissue. 4th edn. Lyon: International Agency for Research and Cancer (IARC) 2008:88\u2013107."},{"key":"2025112109553862000_69.11.1001.20","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0610163104"},{"key":"2025112109553862000_69.11.1001.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2007.06.012"},{"key":"2025112109553862000_69.11.1001.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2011.09.009"},{"key":"2025112109553862000_69.11.1001.23","unstructured":"Shaffer LG , McGowan JJ , Schmid M . An international system for human cytogenetic nomenclature (ISCN 2013), recommendations of the international standing committee on human cytogenetic normenclature. Karger, 2013."},{"key":"2025112109553862000_69.11.1001.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2013.05.003"},{"key":"2025112109553862000_69.11.1001.25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.4346"},{"key":"2025112109553862000_69.11.1001.26","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.048421"},{"key":"2025112109553862000_69.11.1001.27","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21160"},{"key":"2025112109553862000_69.11.1001.28","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.312"},{"key":"2025112109553862000_69.11.1001.29","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25247"},{"key":"2025112109553862000_69.11.1001.30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.8135"},{"key":"2025112109553862000_69.11.1001.31","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13062"},{"key":"2025112109553862000_69.11.1001.32","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrg816","article-title":"The fundamental role of epigenetic events in cancer","volume":"3","author":"Jones","year":"2002","journal-title":"Nat Rev Genet"},{"key":"2025112109553862000_69.11.1001.33","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.01799-07"},{"key":"2025112109553862000_69.11.1001.34","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0000000000000217"}],"container-title":["Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jclinpath-2016-203715","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T17:55:45Z","timestamp":1763747745000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcp.bmj.com\/lookup\/doi\/10.1136\/jclinpath-2016-203715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,15]]},"references-count":34,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2016,10,19]]},"published-print":{"date-parts":[[2016,11]]}},"alternative-id":["10.1136\/jclinpath-2016-203715"],"URL":"https:\/\/doi.org\/10.1136\/jclinpath-2016-203715","relation":{},"ISSN":["0021-9746","1472-4146"],"issn-type":[{"value":"0021-9746","type":"print"},{"value":"1472-4146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,15]]}}}